CANC vs IBRN: Holdings Overlap & Returns

Over the year to Nov 13, 2026, CANC returned +25.2% to IBRN's +19.8%; 0% of their weight is in the same names.

Return gap
+5.4 pts1 year to Nov 13, 2026: CANC ahead, total return
Fee gap
0.28 ptsA year: CANC 0.75%, IBRN 0.47%, per filings dated Nov 21, 2025 and Jun 29, 2026
Overlap
0%Share of the two books held in common, holdings dated Nov 12, 2026
Net flow
–Needs daily flows for both funds
The answerOne drawing that carries it.

Compare two other funds

The evidenceWhy, in charts and cards.
CANC and IBRN · 1 year

Growth of 100

CANC +25.2%IBRN +19.8%
Growth of 100 in CANC and IBRN over 1 year, Nov 13, 2025 to Nov 13, 2026, with distributions reinvested. CANC ends at 125.2 (+25.2%), IBRN at 119.8 (+19.8%).

CANC +25.2%, IBRN +19.8%: CANC +5.4 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.

Share

Use this comparison

Alert

CANC and IBRN flows, by email on Sundays.

One-click unsubscribe. See Privacy.

Hypothetical · drag the order size

Cost to trade

Hypothetical. A $10,000 order in IBRN costs about $16.00 one way and $32.00 in and out, at a median spread of 0.32%. The 0.32% spread is IBRN’s 30-day median, from iShares (fund page).

Hypothetical · drag to set

Fees over time

Hypothetical. $10,000 in CANC for 10 years at 0.75% a year costs about $1,228 in fees and lost growth; IBRN at 0.47% would cost $778. Assumes 6% a year before fees, a sample rate, not a forecast.

How each fund moved

CANC · 1 year to Nov 13, 202677% of its weight is outside the S&P 500
77% of its weight is outside the S&P 50023% of CANC's weight is in S&P 500 companies and 77% is outside the index. Holdings as of Nov 12, 2026.23%77%in the S&P 500of its weight outside the S&P 500active share 96% · top ten 46% of the fund · 55 holdings as published by its issuer for Nov 12, 2026 · Nasdaq-100: 3% in77% of its weight is outside the S&P 50023% of CANC's weight is in S&P 500 companies and 77% is outside the index. Holdings as of Nov 12, 2026.23%77%inoutside the S&P 500active share 96% · Nasdaq-100: 3% in

23% of CANC's weight is in S&P 500 companies and 77% is outside the index. Holdings as of Nov 12, 2026.

IBRN · 1 year to Nov 13, 202695% of its weight is outside the S&P 500
95% of its weight is outside the S&P 5005% of IBRN's weight is in S&P 500 companies and 95% is outside the index. Holdings as of Nov 12, 2026.5%95%inof its weight outside the S&P 500active share 100% · top ten 45% of the fund · 67 holdings as published by its issuer for Nov 12, 2026 · Nasdaq-100: 0% in95% of its weight is outside the S&P 5005% of IBRN's weight is in S&P 500 companies and 95% is outside the index. Holdings as of Nov 12, 2026.5%95%5% of its weight in S&P 500 companiesof its weight outside the S&P 500active share 100% · Nasdaq-100: 0% in

5% of IBRN's weight is in S&P 500 companies and 95% is outside the index. Holdings as of Nov 12, 2026.

Key numbers

CANC in the S&P 500
22.8%
IBRN in the S&P 500
5.3%
CANC total return, 1 year
+25.2%
IBRN total return, 1 year
+19.8%

IBRN costs 0.28 points a year less; their one-year returns differ by 5.4 points; CANC is far larger, $210m against $8.6m.

Pair scorecard

Open the table

Points (pts) are percentage points.

Total return, 1 year+25.2%+19.8%
Below its all-time high9.2%, high on Aug 25, 202615.9%, high on Aug 19, 2026
What it tracksTherapeutics and medical devicesTherapeutics and medical devices
Expense ratio0.75%0.47%
Net assets, as of Nov 12, 2026$210m$8.6m
Holdings in common0%

The numbers behind it

Net assets on Nov 12, 2026: $210m for Tema Oncology ETF and $8.6m for iShares Neuroscience and Healthcare ETF.

Holdings in common uses holdings dated Nov 12, 2026.

What they share

By the books each fund has filed, CANC and IBRN hold 0% of their money in the same securities at the same weight. Holdings dated Nov 12, 2026.

0half (50%)100%

half

0% in common

Only in CANC

Show all 8 holdings
GENMAB A/S5.82%
ELI LILLY & CO5.62%
REVOLUTION MEDICINES INC5.34%
MERCK & CO INC5.03%
BEONE MEDICINES LTD4.34%
COGENT BIOSCIENCES INC4.31%
NOVARTIS AG4.19%
ABBVIE INC3.88%

Only in IBRN

Show all 8 holdings
BIOGEN5.33%
NEUROCRINE BIOSCIENCES5.09%
EDGEWISE THERAPEUTICS4.96%
Alkermes Public Limited Company4.75%
ARGENX SE ADR4.43%
PRAXIS PRECISION MEDICINES4.30%
PTC THERAPEUTICS4.29%
AXOGEN4.28%

Side by side

Open the table
FundTema Oncology ETF · Holds 55 stocks in therapeutics and medical devices, 23% of its weight in S&P 500 companiesiShares Neuroscience and Healthcare ETF · Holds 67 stocks in therapeutics and medical devices, 5% of its weight in S&P 500 companies
IssuerTemaiShares
ThemeTherapeutics and medical devicesTherapeutics and medical devices
In the S&P 50022.8%5.3%
Active share vs the S&P 50095.7%100.0%
In the Nasdaq-1003.1%0.0%
Holdings5567
Top ten, share of the fund45.5%45.2%
Expense ratio0.75%0.47%
Fee for the differing part0.78%0.47%
Total return, 1 year+25.2%+19.8%
vs its benchmarknot measurednot measured
Below its high−9.2%−15.9%
Net assets, as of Nov 12, 2026$210m$8.6m

As of Nov 13, 2026. Source: ETFIQ.

Window by window

Open the table
3 months−3.8%−12.6%
6 months+10.7%−1.7%
1 year+25.2%+19.8%
3 years+85.9%+67.5%
Since launch (Not the same days: CANC Aug 2023 · IBRN Aug 2022)+69.4%+41.2%

About CANC

By weight, 23% of CANC's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 96%. The top ten holdings are 46% of the fund across 55 positions, as published by its issuer for Nov 12, 2026.

More

Over the year to Nov 13, 2026 the fund returned +25.2% with distributions reinvested. It sits 9.2% below its all-time high of Aug 25, 2026.

About IBRN

By weight, 5% of IBRN's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 100%. The top ten holdings are 45% of the fund across 67 positions, as published by its issuer for Nov 12, 2026.

More

Over the year to Nov 13, 2026 the fund returned +19.8% with distributions reinvested. It sits 15.9% below its all-time high of Aug 19, 2026.

0% of the two portfolios are the same securities at the same weight.

Questions people ask

Do CANC and IBRN hold the same stocks?

By their latest filings, 0% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.

Which is more different from the S&P 500, CANC or IBRN?

CANC has 23% of its weight in S&P 500 names and IBRN has 5%, so IBRN differs more from the index.

Which is cheaper, CANC or IBRN?

CANC charges 0.75% a year and IBRN charges 0.47%, so IBRN is cheaper. Fees come from each fund's prospectus.

Other comparisons

Sources

More

Links are sources, not endorsements. A comparison is not a recommendation.

Copy and cite

Cite this pageCitation, APA and Markdown

ETFIQ, CANC against IBRN, data as of Nov 13, 2026. https://etfiq.com/compare/themes/canc-vs-ibrn

Open data

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.